Immunosenescence, inflammation and Alzheimer’s disease

Longevity & Healthspan

Giuseppina Colonna-Romano¹  Giuseppina Candore¹  Calogero Caruso¹  Mariavaleria Pellicanò²  Silvio Buffa¹  Matteo Bulati¹  Adriana Martorana¹ 

[1] Immunosenescence Unit, Department of Pathobiology and Medical and Forensic Biotechnologies, University of Palermo, corso Tukory 211, 90134, Palermo, Italy;Department of Internal Medicine II, Center for Medical Research, Tübingen Aging and Tumor Immunology Group, University of Tübingen, Waldhörnlestraße 22, 72072, Tübingen, Germany

关键词: Ageing;    Lymphocyte;    Chemokine;    Cytokine;    Inflammation;    Alzheimer’s disease;    Immunosenescence;   

Others  :  805276
DOI  :  10.1186/2046-2395-1-8

 received in 2012-06-07, accepted in 2012-07-09,  发布年份 2012

【 摘 要 】

Ageing impacts negatively on the development of the immune system and its ability to fight pathogens. Progressive changes in the T-cell and B-cell systems over the lifespan of individuals have a major impact on the capacity to respond to immune challenges. The cumulative age-associated changes in immune competence are termed immunosenescence that is characterized by changes where adaptive immunity deteriorates, while innate immunity is largely conserved or even upregulated with age. On the other hand, ageing is also characterized by “inflamm-ageing”, a term coined to explain the inflammation commonly present in many age-associated diseases. It is believed that immune inflammatory processes are relevant in Alzheimer’s disease, the most common cause of dementia in older people. In the present paper we review data focusing on changes of some immunoinflammatory parameters observed in patients affected by Alzheimer’s disease.

【 授权许可】

   
2012 Martorana et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Troen BR: The biology of ageing. Mt Sinai J Med 2003, 70:3-22.
• [2]Goldberger AL, Peng CK, Lipsitz LA: What is physiologic complexity and how does it change with aging and disease? Neurobiol Aging 2002, 23:23-26.
• [3]Wick G, Berger P, Jansen-Dürr P, Grubeck-Loebenstein BA: Darwinian-evolutionary concept of age-related diseases. Exp Gerontol 2003, 38:13-25.
• [4]Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listì F, Nuzzo D, Vasto S, Lio D, Caruso C: Biology of longevity: role of the innate immune system. Rejuvenation Res 2006, 9:143-148.
• [5]Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C: The extreme longevity: the state of the art in Italy. Exp Gerontol 2008, 43:45-52.
• [6]Di Bona D, Plaia A, Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C: Association between the interleukin-1β polymorphisms and Alzheimer’s disease: a systematic review and meta-analysis. Brain Res Rev 2008, 59:155-163.
• [7]Di Bona D, Vasto S, Capurso C, Christiansen L, Deiana L, Franceschi C, Hurme M, Mocchegiani E, Rea M, Lio D, Candore G, Caruso C: Effect of interleukin-6 polymorphisms on human longevity: a systematic review and meta-analysis. Ageing Res Rev 2009, 8:36-42.
• [8]Franceschi C, Cossarizza A: Introduction: the reshaping of the immune system with age. Int Rev Immunol 1995, 12:1-4s.
• [9]Cossarizza A, Ortolani C, Paganelli R, Barbieri D, Monti D, Sansoni P, Fagiolo U, Castellani G, Bersani F, Londei M, Franceschi C: CD45 isoforms expression on CD4+ and CD8+ T cells throughout life, from newborns to centenarians: implications for T cell memory. Mech Ageing Dev 1996, 86:173-195.
• [10]Vasto S, Colonna-Romano G, Larbi A, Wikby A, Caruso C, Pawelec G: Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing 2007, 4:2. BioMed Central Full Text
• [11]Pawelec G, Larbi A: Immunity and ageing in man: annual review 2006/2007. Exp Gerontol 2008, 43:34-38.
• [12]Sauce D, Appay V: Altered thymic activity in early life: how does it affect the immune system in young adults? Curr Opin Immunol 2011, 23:543-548.
• [13]Appay V, Fastenackels S, Katlama C, Ait-Mohand H, Schneider L, Guihot A, Keller M, Grubeck-Loebenstein B, Simon A, Lambotte O, Hunt PW, Deeks SG, Costagliola D, Autran B, Sauce D: Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS 2011, 25:1813-1822.
• [14]Pawelec G, McElhaney JE, Aiello AE, Derhovanessian E: The impact of CMV infection on survival in older humans. Curr Opin Immunol 2012, 24:1-5.
• [15]Colonna-Romano G, Cossarizza A, Aquino A, Scialabba G, Bulati M, Lio D, Candore G, Di Lorenzo G, Fradà G, Caruso C: Age- and gender-related values of lymphocyte subsets in subjects from Northern and Southern Italy. Arch Gerontol Geriatr Suppl 2002, 8:99-107.
• [16]Colonna-Romano G, Bulati M, Aquino A, Scialabba G, Candore G, Lio D, Motta M, Malaguarnera M, Caruso C: B cells in the aged: CD27, CD5, and CD40 expression. Mech Ageing Dev 2003, 124:389-393.
• [17]Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K: Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 2005, 175:3262-3267.
• [18]Veneri D, Ortolani R, Franchini M, Tridente G, Pizzolo G, Vella A: Expression of CD27 and CD23 on peripheral blood B lymphocytes in humans of different ages. Blood Transfus 2009, 7:29-34.
• [19]Colonna-Romano G, Bulati M, Aquino A, Pellicanò M, Vitello S, Lio D, Candore G, Caruso C: A double-negative (IgD–CD27–) B cell population is increased in the peripheral blood of elderly people. Mech Ageing Dev 2009, 130:681-690.
• [20]Buffa S, Bulati M, Pellicanò M, Dunn-Walters DK, Wu YC, Candore G, Vitello S, Caruso C, Colonna-Romano G: B cell immunosenescence: different features of naive and memory B cells in elderly. Biogerontology 2011, 12:473-483.
• [21]Listì F, Candore G, Modica MA, Russo M, Di Lorenzo G, Esposito-Pellitteri M, Colonna-Romano G, Aquino A, Bulati M, Lio D, Franceschi C, Caruso C: A study of serum immunoglobulin levels in elderly persons that provides new insights into B cell immunosenescence. Ann N Y Acad Sci 2006, 1089:487-495.
• [22]Chong Y, Ikematsu H, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J: CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(−) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances. Int Immunol 2005, 17:383-390.
• [23]Frasca D, Riley RL, Blomberg BB: Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol 2005, 17:378-384.
• [24]Bulati M, Buffa S, Candore G, Caruso C, Dunn-Walters DK, Pellicanò M, Wu YC, Colonna Romano G: B cells and immunosenescence: a focus on IgG+IgD–CD27– (DN) B cells in aged humans. Ageing Res Rev 2011, 10:274-284.
• [25]Frasca D, Diaz A, Romero M, Phillips M, Mendez NV, Landin AM, Blomberg BB: Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int Immunol 2012, 24:175-182.
• [26]Candore G, Di Lorenzo G, Mansueto P, Melluso M, Fradà G, Li Vecchi M, Esposito Pellitteri M, Drago A, Di Salvo A, Caruso C: Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians. Mech Ageing Dev 1997, 94:183-190.
• [27]Weksler ME, Szabo P: The effect of age on the B-cell repertoire. J Clin Immunol 2000, 20:240-249.
• [28]Gibson KL, Wu YC, Barnett Y, Duggan O, Vaughan R, Kondeatis E, Nilsson BO, Wikby A, Kipling D, Dunn-Walters DK: B-cell diversity decreases in old age and is correlated with poor health status. Ageing Cell 2009, 8:18-25.
• [29]Akbar AN, Henson SM: Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011, 11:289-295.
• [30]Henson SM, Riddell NE, Akbar AN: Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012, 24:1-6.
• [31]Macaulay R, Akbar AN, Henson SM: The role of the T cell in age-related inflammation. Age (Dordr) 2012.
• [32]Blomberg BB, Frasca D: Quantity, not quality, of antibody response decreased in the elderly. J Clin Invest 2011, 121:2981-2983.
• [33]Wolf J, Weinberger B, Grubeck-Loebenstein B: The immunoregulatory effects of CMV-infection in human fibroblasts and the impact on cellular senescence. Immun Ageing 2012, 9:1-6. BioMed Central Full Text
• [34]Herndler-Brandstetter D, Landgraf K, Tzankov A, Jenewein B, Brunauer R, Laschober GT, Parson W, Kloss F, Gassner R, Lepperdinger G, Grubeck-Loebenstein B: The impact of aging on memory T cell phenotype and function in the human bone marrow. J Leukoc Biol 2012, 91:197-205.
• [35]Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilsson BO, Ernerudh J, Pawelec G, Johansson B: An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci 2005, 60:556-565.
• [36]Strindhall J, Nilsson BO, Löfgren S, Ernerudh J, Pawelec G, Johansson B, Wikby A: No immune risk profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol 2007, 42:753-761.
• [37]Wikby A, Månsson IA, Johansson B, Strindhall J, Nilsson SE: The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20–100 years of age. Biogerontology 2008, 9:299-308.
• [38]Vasto S, Caruso C: Immunity & Ageing: a new journal looking at ageing from an immunological point of view. Immun Ageing 2004, 1:1-4. BioMed Central Full Text
• [39]Krabbe KS, Pedersen M, Bruunsgaard H: Inflammatory mediators in the elderly. Exp Gerontol 2004, 39:687-699.
• [40]Bruunsgaard H: The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. Dan MedBull 2006, 53:285-309.
• [41]De Martinis M, Franceschi C, Monti D, Ginaldi L: Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 2005, 579:2035-2039.
• [42]Spirig R, Tsui J, Shaw S: The emerging role of TLR and innate immunity in cardiovascular disease. Cardiol Res Pract 2012, 2012:181394.
• [43]Gui T, Shimokado A, Sun Y, Akasaka T, Muragaki Y: Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediators Inflamm 2012, 2012:693083.
• [44]Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867.
• [45]Shacter E, Weitzman SA: Chronic inflammation and cancer. Oncology 2002, 16:217-226.
• [46]Rubin DC, Shaker A, Levin MS: Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012, 3:107.
• [47]Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobagyi GN, Ueno NT: Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012, 17:891-899.
• [48]Wimo A, Jonsson L, Winblad B: An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006, 21:175-181.
• [49]Rubio-Perez JM, Morillas-Ruiz JM: A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal 2012, 2012:756357.
• [50]Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60:1119-1122.
• [51]Candore G, Balistreri CR, Colonna-Romano G, Lio D, Listì F, Vasto S, Caruso C: Gender-related immune-inflammatory factors, age-related diseases, and longevity. Rejuvenation Res 2010, 13:292-297.
• [52]Luciano M, Marioni RE, Gow AJ, Starr JM, Deary IJ: Reverse causation in the association between C reactive protein and fibrinogen levels and cognitive abilities in an aging sample. Psychosom Med 2009, 71:404-409.
• [53]Henderson VW: Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006, 138:1031-1039.
• [54]Müller UC, Zheng H: Physiological functions of APP family proteins. Cold Spring Harb Perspect Med 2012, 2:a006288.
• [55]Braak H, Del Tredici K: The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol 2011, 121:171-181.
• [56]Griffin WS, Mrak RE: Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease. J Leukoc Biol 2002, 72:233-238.
• [57]Cacquevel M, Lebeurrier N, Cheenne S, Vivien D: Cytokines in neuroinflammation and Alzheimer’s disease. Curr Drug Targets 2004, 5:529-534.
• [58]Finch CE, Morgan TE: Systemic inflammation, infection, ApoE alleles, and Alzheimer disease: a position paper. Curr Alzheimer Res 2007, 4:185-189.
• [59]Town T, Nikolic V, Tan J: The microglial ‘activation’ continuum: from innate to adaptive responses. J Neuroinflammation 2005, 2:24-33. BioMed Central Full Text
• [60]Friedlander RM: Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003, 348:1365-1375.
• [61]Atwood CS, Obrenovich ME, Liu T: Amyloid-β: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-β. Brain Res Rev 2003, 43:1-16.
• [62]Lindberg C, Hjorth E, Post C, Winblad B, Schultzberg M: Cytokine production by a human microglial cell line: effects ofβ-amyloid andα-melanocyte-stimulating hormone. Neurotox Res 2005, 8:267-276.
• [63]Pellicanò M, Bulati M, Buffa S, Barbagallo M, Di Prima A, Misiano G, Picone P, Di Carlo M, Nuzzo D, Candore G, Vasto S, Lio D, Caruso C, Colonna-Romano G: Systemic immune responses in Alzheimer’s disease: in vitro mononuclear cell activation and cytokine production. J Alzheimers Dis 2010, 21:181-192.
• [64]Ferretti MT, Cuello AC: Does a pro-inflammatory process precede Alzheimer’s disease and mild cognitive impairment? Curr Alzheimer Res 2011, 8:164-174.
• [65]Strang F, Scheichl A, Chen YC, Wang X, Htun NM, Bassler N, Eisenhardt S, Habersberger J, Peter K: Amyloid plaques dissociate pentameric to monomeric C-Reactive-Protein: a novel pathomechanism driving cortical inflammation in Alzheimer’s disease? Brain Pathol 2012, 22:337-346.
• [66]Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, Zhao J: Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007, 21:284-294.
• [67]Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, et al.: Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009, 105:128-137.
• [68]Pepys MB, Hirschfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111:1805-1812.
• [69]Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V: Systemic immune aberrations in Alzheimer’s disease patients. J Neuroimmunol 2008, 193:183-187.
• [70]Miscia S, Ciccocioppo F, Lanuti P, Velluto L, Bascelli A: Aβ(1–42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol Aging 2009, 30:394-406.
• [71]Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD: Peripheral T cells derived from Alzheimer’s disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-α-dependent. Neurobiol Aging 2010, 31:175-188.
• [72]Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe DJ, Weiner HL: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer’s disease. J Clin Invest 2003, 112:415-422.
• [73]Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G: Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer’s disease patients. J Alzheimers Dis 2005, 7:221-232.
• [74]Britschgi M, Wyss-Coray T: Systemic and acquired immune responses in Alzheimer’s disease. Int Rev Neurobiol 2007, 82:205-233.
• [75]Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, Pawelec G: Immune profiling of Alzheimer patients. J Neuroimmunol 2012, 242:52-59.
• [76]Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G: Alzheimer’s disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 2011, 11:149-153.
• [77]Reale M, Iarlori C, Gambi F, Lucci I, Salvatore M, Gambi D: Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer’s disease patients. Exp Gerontol 2005, 40:165-171.
• [78]Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L, Chen YH: Peripheral T cells overexpress MIP-1α to enhance its transendothelial migration in Alzheimer’s disease. Neurobiol Aging 2007, 28:485-496.
• [79]Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T: Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J Alzheimers Dis 2009, 17:91-103.
• [80]Sastre M, Richardson JC, Gentleman SM, Brooks DJ: Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr Alzheimer Res 2011, 8:132-141.
• [81]Richartz-Salzburger E, Batra A, Stransky E, Laske C, Köhler N, Bartels M, Buchkremer G, Schott K: Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res 2007, 41:174-178.
• [82]Speciale L, Calabrese E, Saresella M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P: Lymphocyte subset patterns and cytokine production in Alzheimer’s disease patients. Neurobiol Aging 2007, 28:1163-1169.
• [83]Xue SR, Xu DH, Yang XX, Dong WL: Alterations in lymphocyte subset patterns and co-stimulatory molecules in patients with Alzheimer disease. Chin Med J (Engl) 2009, 122:1469-1472.
• [84]Jóźwik A, Landowski J, Bidzan L, Fülop T, Bryl E, Witkowski JM: Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. PLoS One 2012, 7:e33276.
• [85]Querfurth HW, LaFerla FM: Alzheimer’s disease. N Engl J Med 2010, 362:329-344.
• [86]Teeling JL, Perry VH: Systemic infection and inflammation in acute CNS injury and chronic neurodegeneration: underlying mechanisms. Neuroscience 2009, 158:1062-1073.
• [87]Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH: Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood–brain barrier. J Immunol 2009, 182:5778-5788.
• [88]Reale M, Iarlori C, Feliciani C, Gambi D: Peripheral chemokine receptors, their ligands, cytokines and Alzheimer’s disease. J Alzheimers Dis 2008, 14:147-159.
• [89]Iarlori C, Gambi D, Gambi F, Lucci I, Feliciani C, Salvatore M, Reale M: Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer’s disease. Exp Gerontol 2005, 40:605-611.
• [90]Stuart LM, Bell SA, Stewart CR, Silver JM, Richard J, Goss JL, Tseng AA, Zhang A, El Khoury JB, Moore KJ: CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex. J Biol Chem 2007, 282:27392-27401.
• [91]Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM: The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs 2009, 10:672-680.
• [92]Buchanan MM, Hutchinson M, Watkins LR, Yin H: Toll-like receptor 4 in CNS pathologies. J Neurochem 2010, 114:13-27.
• [93]González-Navajas JM, Fine S, Law J, Datta SK, Nguyen KP, Yu M, Corr M, Katakura K, Eckman L, Lee J, Raz E: TLR4 signaling in effector CD4+ T cells regulates TCR activation and experimental colitis in mice. J Clin Invest 2010, 120:570-581.